One Size Does Not Fit All: Challenging Some Dogmas and Taboos in Drug Discovery
- 21 December 2015
- journal article
- review article
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 8 (1) , 29-38
Abstract
Advances in genetics, biology, chemical synthesis and computational methods have contributed to the understanding of diseases and drugs and with all of the above, there is an expectation that we are in a better position than ever before to create effective medicines for our needs. The reality is, however, disconnected from the expectation – US FDA drug approval statistics show that the number of approved drugs, especially the first-in-class drugs, is not commensurate with our improved knowledge. In this perspective, we offer our views on the possible reasons for this, focusing on small-molecule drugs and suggest some ideas for further considerations.Keywords
This publication has 54 references indexed in Scilit:
- 2014 FDA drug approvalsNature Reviews Drug Discovery, 2015
- Drug discovery in pharmaceutical industry: productivity challenges and trendsDrug Discovery Today, 2012
- Four Lessons from Global Health Drug Discovery: Medicine for an Ailing Industry?ACS Medicinal Chemistry Letters, 2012
- Drug discovery in the next decade: innovation needed ASAPDrug Discovery Today, 2012
- Principles of early drug discoveryBritish Journal of Pharmacology, 2011
- Productivity Shortfalls in Drug Discovery: Contributions from the Preclinical Sciences?The Journal of Pharmacology and Experimental Therapeutics, 2011
- Case histories, magic bullets and the state of drug discoveryNature Reviews Drug Discovery, 2006
- Can the pharmaceutical industry reduce attrition rates?Nature Reviews Drug Discovery, 2004
- Drug research: myths, hype and realityNature Reviews Drug Discovery, 2003
- The Value of Reporting Therapeutic Ineffectiveness as an Adverse Drug ReactionDrug Safety, 2000